

Title (en)
COMBINATION THERAPY WITH AZD2171 AND 5-FU AND/OR CPT-11

Title (de)
KOMBINATIONSTHERAPIE MIT AZD2171 UND 5-FU UND/ODER CPT-11

Title (fr)
POLYTHERAPIE AVEC L'AZD2171 ET 5-FU ET/OU CPT-11

Publication
EP 1729808 B1 20091111 (EN)

Application
EP 05729381 A 20050322

Priority
• GB 2005001080 W 20050322
• GB 0406446 A 20040323

Abstract (en)
[origin: US2008125447A1] The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of AZD2171 in combination with 5-FU, CPT-11 or 5-FU and CPT-11; to a pharmaceutical composition comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11; to a combination product comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11 for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11; to the use of AZD2171 and 5-FU, CPT-11 or 5-FU and CPT-11 in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

IPC 8 full level
A61K 45/06 (2006.01); **A61K 31/4745** (2006.01); **A61K 31/4965** (2006.01); **A61K 31/517** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP KR US)
A61K 31/4738 (2013.01 - KR); **A61K 31/4745** (2013.01 - EP KR US); **A61K 31/4965** (2013.01 - EP KR US); **A61K 31/517** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP KR US); **A61P 3/10** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 9/14** (2018.01 - EP); **A61P 13/12** (2018.01 - EP); **A61P 15/00** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/02** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

C-Set (source: EP US)
1. **A61K 31/4745 + A61K 2300/00**
2. **A61K 31/4965 + A61K 2300/00**
3. **A61K 31/517 + A61K 2300/00**

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
HR LV

DOCDB simple family (publication)
WO 2005092303 A2 20051006; WO 2005092303 A3 20061102; AT E447974 T1 20091115; AU 2005225193 A1 20051006; AU 2005225193 B2 20081009; BR PI0508982 A 20070828; CA 2610628 A1 20051006; CN 1964742 A 20070516; DE 602005017591 D1 20091224; EP 1729808 A2 20061213; EP 1729808 B1 20091111; ES 2335292 T3 20100324; GB 0406446 D0 20040428; HK 1096023 A1 20070525; IL 177952 A0 20070704; JP 2007530518 A 20071101; KR 20060130763 A 20061219; MX PA06010758 A 20061215; NO 20064755 L 20061020; NZ 549553 A 20091224; US 2008125447 A1 20080529; ZA 200607555 B 20080528

DOCDB simple family (application)
GB 2005001080 W 20050322; AT 05729381 T 20050322; AU 2005225193 A 20050322; BR PI0508982 A 20050322; CA 2610628 A 20050322; CN 200580009218 A 20050322; DE 602005017591 T 20050322; EP 05729381 A 20050322; ES 05729381 T 20050322; GB 0406446 A 20040323; HK 07103005 A 20070320; IL 17795206 A 20060907; JP 2007504467 A 20050322; KR 20067021774 A 20061020; MX PA06010758 A 20050322; NO 20064755 A 20061020; NZ 54955305 A 20050322; US 59423305 A 20050322; ZA 200607555 A 20060908